Published in Int J Colorectal Dis on January 19, 2007
The influence of micrometastases on prognosis and survival in stage I-II colon cancer patients: the Enroute⊕ Study. BMC Surg (2011) 0.96
Patterns of colorectal cancer care in Europe, Australia, and New Zealand. J Natl Cancer Inst Monogr (2013) 0.93
Sigmoid carcinoma in an inguinal hernia: a blessing in disguise? Case Rep Surg (2013) 0.93
Evaluation of clinical, laboratory and morphologic prognostic factors in colon cancer. World J Surg Oncol (2008) 0.89
The expression ratio of Map7/B2M is prognostic for survival in patients with stage II colon cancer. Int J Oncol (2008) 0.85
Screening mammography use and chemotherapy among female stage II colon cancer patients: a retrospective cohort study. BMC Health Serv Res (2010) 0.81
Impact of using elastic stains for detection of venous invasion in the prognosis of patients with lymph node negative colorectal cancer. Int J Colorectal Dis (2010) 0.77
Associations between CYP1A1 rs1048943 A > G and rs4646903 T > C genetic variations and colorectal cancer risk: Proof from 26 case-control studies. Oncotarget (2016) 0.77
Prognostic Effect of Ultra-Staging Node-Negative Colon Cancer Without Adjuvant Chemotherapy: A Prospective National Cancer Institute-Sponsored Clinical Trial. J Am Coll Surg (2015) 0.76
GATA2 rs2335052 Polymorphism Predicts the Survival of Patients with Colorectal Cancer. PLoS One (2015) 0.75
Prognostic factors for patients with stage II colon cancer: results of a prospective study. Int J Colorectal Dis (2016) 0.75
Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med (2000) 19.56
Cancer statistics, 2004. CA Cancer J Clin (2004) 15.72
A comparison of observational studies and randomized, controlled trials. N Engl J Med (2000) 14.11
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med (1990) 11.57
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med (2001) 7.59
Population-based linkage of health records in Western Australia: development of a health services research linked database. Aust N Z J Public Health (1999) 7.57
Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol (2004) 7.36
NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA (1990) 5.77
Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet (2000) 5.04
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04) J Clin Oncol (1999) 4.79
Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol (1999) 3.89
Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies. Lancet (2001) 3.71
Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials. Lancet (2001) 3.32
American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer (2000) 2.80
The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin (2004) 2.65
Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol (2002) 2.51
Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol (2002) 2.33
Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol (1995) 2.02
Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol (2002) 1.93
Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol (2004) 1.86
The National Cancer Data Base. Report on colon cancer. Cancer (1996) 1.53
Adjuvant therapy of colon cancer. CA Cancer J Clin (2001) 1.51
Population-based study of prognostic factors in stage II colonic cancer. Br J Surg (2006) 1.16
Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer (2005) 1.13
Influence of sex and age on fluorouracil clearance. J Clin Oncol (1992) 1.10
Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol (1994) 1.04
Adjuvant therapy for stage II colon cancer: an elephant in the living room? Ann Oncol (2004) 1.00
Efficacy of adjuvant fluorouracil and leucovorin in stage B2 and C colon cancer. International Multicenter Pooled Analysis of Colon Cancer Trials Investigators. Semin Oncol (2001) 0.87
Weekly 5-fluorouracil and leucovorin: achieving lower toxicity with higher dose-intensity in adjuvant chemotherapy after colorectal cancer resection. Ann Oncol (2004) 0.79
FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer. J Clin Oncol (2005) 0.76
Adjuvant chemotherapy for stage II colon cancer: the time has come. Eur J Surg Oncol (2000) 0.75
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89
Cetuximab for the treatment of colorectal cancer. N Engl J Med (2007) 13.39
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol (2006) 7.33
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet (2012) 6.21
Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol (2008) 6.01
Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol (2003) 5.84
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med (2014) 4.71
The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol (2005) 3.48
Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology (2002) 2.85
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. Cancer (2010) 2.73
CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res (2003) 2.48
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol (2012) 2.45
Comparing survival outcomes for patients with colorectal cancer treated in public and private hospitals. Med J Aust (2007) 2.19
Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl (2008) 2.04
Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst (2008) 1.95
PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat (2005) 1.89
Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology (2005) 1.82
The effect of a smoke-free law on restaurant business in South Australia. Aust N Z J Public Health (2002) 1.80
A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. J Mol Diagn (2009) 1.76
Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial. Lung Cancer (2006) 1.75
Fruit and vegetable consumption and the risk of proximal colon, distal colon, and rectal cancers in a case-control study in Western Australia. J Am Diet Assoc (2011) 1.68
BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol Cancer (2006) 1.68
Model for collecting colorectal cancer staging information in Western Australia. ANZ J Surg (2004) 1.63
MicroRNA-130b regulates the tumour suppressor RUNX3 in gastric cancer. Eur J Cancer (2010) 1.57
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res (2013) 1.55
Retransplantation for hepatitis C: results of a U.S. multicenter retransplant study. Liver Transpl (2007) 1.54
Squamoproliferative lesions arising in the setting of BRAF inhibition. Am J Dermatopathol (2012) 1.51
Women who smoke like men die like men who smoke: findings from two Australian cohort studies. Tob Control (2011) 1.50
DNA hypermethylation in breast cancer and its association with clinicopathological features. Cancer Lett (2005) 1.48
Heterogeneous staining for mismatch repair proteins during population-based prescreening for hereditary nonpolyposis colorectal cancer. J Mol Diagn (2007) 1.48
Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy. Clin Cancer Res (2008) 1.48
Host response to colorectal cancer. ANZ J Surg (2008) 1.47
Low cytosine triphosphate synthase 2 expression renders resistance to 5-fluorouracil in colorectal cancer. Cancer Biol Ther (2011) 1.45
Audit of patients with mesothelioma treated with pemetrexed in a single institution in Western Australia. Asia Pac J Clin Oncol (2010) 1.40
Image analysis algorithms for immunohistochemical assessment of cell death events and fibrosis in tissue sections. J Histochem Cytochem (2009) 1.38
The folate pool in colorectal cancers is associated with DNA hypermethylation and with a polymorphism in methylenetetrahydrofolate reductase. Clin Cancer Res (2003) 1.35
Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features. BMC Cancer (2010) 1.32
Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin Cancer Res (2009) 1.32
Effect of feedback regarding urinary cotinine and brief tailored advice on home smoking restrictions among low-income parents of children with asthma: a controlled trial. Prev Med (2002) 1.32
Hodgkin lymphoma-related vanishing bile duct syndrome and idiopathic cholestasis: statistical analysis of all published cases and literature review. Acta Oncol (2008) 1.31
The Zon laboratory guide to positional cloning in zebrafish. Methods Cell Biol (2004) 1.30
CD133 expression predicts for non-response to chemotherapy in colorectal cancer. Mod Pathol (2010) 1.29
Epstein-Barr virus, human papillomavirus and mouse mammary tumour virus as multiple viruses in breast cancer. PLoS One (2012) 1.28
Non-resection versus resection for an asymptomatic primary tumour in patients with unresectable stage IV colorectal cancer. Cochrane Database Syst Rev (2012) 1.27
Measurement of lung tumor volumes using three-dimensional computer planning software. Int J Radiat Oncol Biol Phys (2002) 1.25
Homocysteine and depression in later life. Arch Gen Psychiatry (2008) 1.24
The omentum. World J Gastroenterol (2000) 1.19
Indwelling pleural catheters reduce inpatient days over pleurodesis for malignant pleural effusion. Chest (2012) 1.18
Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation. Liver Transpl (2012) 1.18
Population-based detection of Lynch syndrome in young colorectal cancer patients using microsatellite instability as the initial test. Int J Cancer (2009) 1.17
Detection of BRAF V600E mutation by pyrosequencing. Pathology (2008) 1.16
Prognostic significance of microsatellite instability and Ki-ras mutation type in stage II colorectal cancer. Oncology (2003) 1.16
Expression of sFRP-4 and beta-catenin in human colorectal carcinoma. Cancer Lett (2006) 1.15
Non-cell autonomous requirement for the bloodless gene in primitive hematopoiesis of zebrafish. Development (2002) 1.14
Mutations in the MYB intron I regulatory sequence increase transcription in colon cancers. Genes Chromosomes Cancer (2006) 1.13
A distinctive colour associated with high iodine content in malignant pleural effusion from metastatic papillary thyroid cancer: a case report. J Med Case Rep (2013) 1.12
Meta-analysis of genetic polymorphisms and gastric cancer risk: variability in associations according to race. Eur J Cancer (2009) 1.10
A randomised phase III study of palliative radiation with concomitant carboplatin for brain metastases from non-small cell carcinoma of the lung. Lung Cancer (2004) 1.09
Re: five-year results of surgical colorectal cancer treatment in rural Australia. ANZ J Surg (2013) 1.07
Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region. Pathology (2012) 1.07
The role of TIPS for portal vein patency in liver transplant patients with portal vein thrombosis. Liver Transpl (2006) 1.03
Gene discovery in familial cancer syndromes by exome sequencing: prospects for the elucidation of familial colorectal cancer type X. Mod Pathol (2012) 1.01
A multisite blinded study for the detection of BRAF mutations in formalin-fixed, paraffin-embedded malignant melanoma. Sci Rep (2013) 1.01
A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. Clin Genitourin Cancer (2013) 1.00
Outcome for patients with malignant pleural mesothelioma referred for Trimodality therapy in Western Australia. J Thorac Oncol (2009) 0.99
Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma. Melanoma Res (2014) 0.97
Gastrointestinal stromal tumours (GISTs): a clinicopathological and molecular study of 66 cases. Pathology (2005) 0.97
Target gene mutation profile differs between gastrointestinal and endometrial tumors with mismatch repair deficiency. Cancer Res (2002) 0.96
Genetic polymorphisms in the MMP-2 and MMP-9 genes and breast cancer phenotype. Breast Cancer Res Treat (2004) 0.96
Phosphatidylinositol-3-kinase pathway aberrations in gastric and colorectal cancer: meta-analysis, co-occurrence and ethnic variation. Int J Cancer (2013) 0.96
A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma. Invest New Drugs (2006) 0.94
A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma. Cancer (2009) 0.94
Breast cancer in Western Australia: clinical practice and clinical guidelines. Med J Aust (2004) 0.94
Risk factors at pretreatment predicting treatment-induced nausea and vomiting in Australian cancer patients: a prospective, longitudinal, observational study. Support Care Cancer (2010) 0.94
Screening for defective DNA mismatch repair in stage II and III colorectal cancer patients. Clin Gastroenterol Hepatol (2004) 0.93
Detection of epidermal growth factor receptor variations by partially denaturing HPLC. Clin Chem (2006) 0.92
Lack of association between CCND1 G870A polymorphism and the risk of breast and colorectal cancers. Anticancer Res (2003) 0.91
Differential effects of donor and recipient IL28B and DDX58 SNPs on severity of HCV after liver transplantation. J Hepatol (2013) 0.90
Colorectal cancer surgical care and survival: do private health insurance, socioeconomic and locational status make a difference? ANZ J Surg (2005) 0.90
Exome versus transcriptome sequencing in identifying coding region variants. Expert Rev Mol Diagn (2012) 0.90
Wnt antagonist, secreted frizzled-related protein 4 (sFRP4), increases chemotherapeutic response of glioma stem-like cells. Oncol Res (2013) 0.90
Underreporting of liver transplant waitlist removals due to death or clinical deterioration: results at four major centers. Transplantation (2013) 0.89
Timing and intensity of recreational physical activity and the risk of subsite-specific colorectal cancer. Cancer Causes Control (2011) 0.89
Efficacy of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): analysis of the Australian subpopulation of the TRUST study. Asia Pac J Clin Oncol (2012) 0.89
BRAF mutation is associated with the CpG island methylator phenotype in colorectal cancer from young patients. Cancer Lett (2008) 0.89
Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol (2013) 0.89
Patients with colorectal tumors with microsatellite instability and large deletions in HSP110 T17 have improved response to 5-fluorouracil–based chemotherapy. Gastroenterology (2014) 0.88
Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells. J Transl Med (2012) 0.88
Lung cancer clinicians' preferences for adjuvant chemotherapy in non-small-cell lung cancer: what makes it worthwhile? Lung Cancer (2011) 0.87
Surgical management of lung cancer in Western Australia in 1996 and its outcomes. ANZ J Surg (2004) 0.87
SPARC, FOXP3, CD8 and CD45 correlation with disease recurrence and long-term disease-free survival in colorectal cancer. PLoS One (2011) 0.87